|Mr. Raul R. Rodriguez||862.37k||N/A||56|
|Mr. Ryan D. Maynard||603.5k||N/A||48|
|Ms. Dolly A. Vance||650.8k||N/A||52|
|Dr. Anne-Marie S. Duliege M.D., M.S.||541.2k||N/A||58|
|Mr. Eldon C. Mayer III||175.92k||N/A||56|
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companys clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.
Rigel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 15, 2017 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 4; Compensation: 7.